Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing
Avinaash Maharaj(Queen Mary University of London), Louise Metherell(Queen Mary University of London), Bertrand Cariou(Institut du Thorax), John C. Achermann(Institute of Child Health), Gerard Ruiz‐Babot(Harvard Stem Cell Institute), Federica Buonocore(Institute of Child Health), Neikelyn Burgos-Tirado(University of Michigan), Juan Pedro López‐Siguero, Stephanie Johnson(The University of Queensland), D. Drui(Centre Hospitalier Universitaire de Nantes), Tülay Güran(Marmara University), Fatih Gürbüz(Cukurova University), Eirini Meimaridou(Queen Mary University of London), Helen Spoudeas(Great Ormond Street Hospital), Jenifer P. Suntharalingham(University College London), Cameron P. Capper(University of Michigan), Malcolm Donaldson(University of Glasgow), Rathi Prasad(Queen Mary University of London), Emma L. Duncan(King's College London), Bilgin Yüksel(Cukurova University), Peter C. Hindmarsh(Royal London Hospital), Dallas Fowler(The University of Queensland), Aideen McInerney‐Leo(Queensland University of Technology), Richard J. Auchus(University of Michigan), S Gupta(Hull Royal Infirmary), Louise S. Conwell(Children's Medical Research Institute), Claire Hughes(Queen Mary University of London), Robert S. Lindsay(National Institutes of Health), Ashwini Maudhoo(Queen Mary University of London), Hwei‐Ming Peng(University of Michigan), Elizabeth Crowne(University Hospitals Bristol NHS Foundation Trust), Niccolò Striglioni(Great Ormond Street Hospital), Mark Harris(The University of Sydney), Leonardo Guasti(Queen Mary University of London), Robert Couch(University of Alberta), Timothy Cheetham(Newcastle University), Caroline Brain(Great Ormond Street Hospital)
Cited by 37
Related Papers
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture
|Nature Genetics|2012|1.2k
Adiponectin and development of type 2 diabetes in the Pima Indian population
|The Lancet|2002|1.1k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750